Activation of the NOTCH pathway in head and neck cancer.

NOTCH1 mutations have been reported to occur in 10% to 15% of head and neck squamous cell carcinomas (HNSCC). To determine the significance of thesemutations, we embarked upon a comprehensive study ofNOTCH signaling in a cohort of 44 HNSCC tumors and 25 normal mucosal samples through a set of expression, copy number, methylation, and mutation analyses. Copy number increases were identified in NOTCH pathway genes, including the NOTCH ligand JAG1. Gene set analysis defined a differential expression of the NOTCH signaling pathway in HNSCC relative to normal tissues. Analysis of individual pathway-related genes revealed overexpression of ligands JAG1 and JAG2 and receptor NOTCH3. In 32% of the HNSCC examined, activation of the downstream NOTCH effectors HES1/HEY1 was documented. Notably, exomic sequencing identified 5 novel inactivating NOTCH1mutations in 4 of the 37 tumors analyzed, with none of these tumors exhibitingHES1/HEY1 overexpression. Our results revealed a bimodal pattern of NOTCH pathway alterations in HNSCC, with a smaller subset exhibiting inactivating NOTCH1 receptor mutations but a larger subset exhibiting otherNOTCH1 pathway alterations, including increases in expression or gene copy number of the receptor or ligands as well as downstream pathway activation. Our results imply that therapies that target the NOTCH pathway may be more widely suitable for HNSCC treatment than appreciated currently. Cancer Res; 74(4); 1091–104. 2013 AACR.

[1]  R. Tibshirani,et al.  Outlier sums for differential gene expression analysis. , 2007, Biostatistics.

[2]  R. Gibbs,et al.  Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. , 2013, Cancer discovery.

[3]  Steven S. Chang,et al.  Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance , 2011, Clinical Cancer Research.

[4]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[5]  Larry Kedes,et al.  HES and HERP families: Multiple effectors of the notch signaling pathway , 2003, Journal of cellular physiology.

[6]  J. Manola,et al.  The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins , 2009, Clinical Cancer Research.

[7]  A. Giaccia,et al.  Notch1 is an effector of Akt and hypoxia in melanoma development. , 2008, The Journal of clinical investigation.

[8]  J. Califano,et al.  Promoter methylation and loss of p16INK4a gene expression in head and neck cancer , 2012, Head & neck.

[9]  Matthew E Ritchie,et al.  Integrative analysis of RUNX1 downstream pathways and target genes , 2008, BMC Genomics.

[10]  S. Armstrong,et al.  Cancer: The flipside of Notch , 2011, Nature.

[11]  Raphael Kopan,et al.  The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.

[12]  K. Frazer,et al.  Microdroplet-based PCR amplification for large scale targeted sequencing , 2009, Nature Biotechnology.

[13]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[14]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[15]  O. Abdel-Wahab,et al.  A novel tumor suppressor function for the Notch pathway in myeloid leukemia , 2011, Nature.

[16]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[17]  Ruud H. Brakenhoff,et al.  The molecular biology of head and neck cancer , 2011, Nature Reviews Cancer.

[18]  G. Lockwood,et al.  High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. , 2005, Cancer research.

[19]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[20]  G. Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Permutation P -values Should Never Be Zero: Calculating Exact P -values When Permutations Are Randomly Drawn , 2011 .

[21]  N. Tsuchida,et al.  Oncogenic mutations of the PIK 3 CA gene in head and neck squamous cell carcinomas , 2022 .

[22]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[23]  Wessel N van Wieringen,et al.  Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer , 2008, Genes, chromosomes & cancer.

[24]  Y. Okada,et al.  Expression Profiles and Clinical Correlations of Degradome Components in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma , 2010, Clinical Cancer Research.

[25]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[26]  Jian Wang,et al.  Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. , 2006, Genes & development.

[27]  W. Hong,et al.  Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  David Haussler,et al.  Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma , 2011, Proceedings of the National Academy of Sciences.

[29]  Eun Sung Park,et al.  Identification of potential driver genes in human liver carcinoma by genomewide screening. , 2009, Cancer research.

[30]  Hao Wang,et al.  Detection of TIMP3 Promoter Hypermethylation in Salivary Rinse as an Independent Predictor of Local Recurrence-Free Survival in Head and Neck Cancer , 2012, Clinical Cancer Research.

[31]  M S German,et al.  Regulation of the pancreatic pro-endocrine gene neurogenin3. , 2001, Diabetes.

[32]  Yibin Kang,et al.  Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. , 2011, Cancer cell.

[33]  Matthew E Ritchie,et al.  Using the R Package crlmm for Genotyping and Copy Number Estimation. , 2011, Journal of statistical software.

[34]  Susumu Goto,et al.  The KEGG resource for deciphering the genome , 2004, Nucleic Acids Res..

[35]  H. Hirata,et al.  Hes1 Directly Controls Cell Proliferation through the Transcriptional Repression of p27Kip1 , 2005, Molecular and Cellular Biology.

[36]  Robert Gentleman,et al.  matchprobes: a Bioconductor package for the sequence-matching of microarray probe elements , 2004, Bioinform..

[37]  K. Choy,et al.  Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV‐associated nasopharyngeal carcinoma , 2012, The Journal of pathology.

[38]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[39]  Rafael A. Irizarry,et al.  A framework for oligonucleotide microarray preprocessing , 2010, Bioinform..

[40]  J. Minna,et al.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. , 2000, Journal of the National Cancer Institute.

[41]  A. Fischer,et al.  Hey Basic Helix-Loop-Helix Transcription Factors Are Repressors of GATA4 and GATA6 and Restrict Expression of the GATA Target Gene ANF in Fetal Hearts , 2005, Molecular and Cellular Biology.

[42]  G. Goodall,et al.  The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. , 2011, The Journal of clinical investigation.

[43]  Alfonso Martinez Arias,et al.  Cell and molecular biology of Notch. , 2007, The Journal of endocrinology.

[44]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[45]  P J F Snijders,et al.  Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus , 2006, Oncogene.

[46]  N. Raben,et al.  Hes-1, a known transcriptional repressor, acts as a transcriptional activator for the human acid alpha-glucosidase gene in human fibroblast cells. , 2002, Biochemical and biophysical research communications.